Tulathromycin is a macrolide antibiotic commonly used for the treatment of respiratory disease in food animal species including goats. Recent research in pigs has suggested that the presence of disease could alter the pharmacokinetics of tulathromycin in animals with respiratory disease. The objectives of this study were (a) compare the plasma pharmacokinetics of tulathromycin in healthy goats as well as goats with an induced respiratory disease; and (b) to compare the tissue residue concentrationss of tulathromycin marker in both groups. For this trial, disease was induced with Pasteurella multocida. Following disease induction tulathromycin was administered. Samples of plasma were collected at various time points up to 312 hours post-treatment, when study animals were euthanized and tissue samples were collected. For PK parameters in plasma, Vz (control: 28.7 ± 11.9 mL/kg; experimental: 57.8 ± 26.6 mL/kg), was significantly higher (P =0.0454) in the experimental group than the control group, and non-significant differences were noted in other parameters. Among time points significantly lower plasma concentrations were noted in the experimental group at 168 hours (P = 0.023), 216 hours (P = 0.036), 264 hours (P = 0.0017), 288 hours (P = 0.0433), and 312 hours (P = 0.0486). None of the goats had tissue residues above the US bovine limit of 5 µg/g at the end of the study.  No differences were observed between muscle, liver, or fat concentrations. A significantly lower concentration (P = 0.0095) was noted in the kidneys of experimental goats when compared to the control group. These results suggest that the effect of respiratory disease on the pharmacokinetics and tissue residues appear minimal after experimental P. multocida infection, but there is the potential for alterations in diseased vs clinical animals.